CIRM-funded clinical trial continues to demonstrate safety of stem cells

We have reported extensively in the past about the clinical trials being funded by the California Institute for Regenerative Medicine (CIRM) on spinal cord injuries identified as acute which involved the use of embryonic stem cells. Now comes word that the trials have successfully enrolled 25 recently-injured individuals who received anywhere from 2 million to 20 million cells and none have reported any serious side effects or loss of function.

The company conducting the trials, Alameda-based BioTime, acquired Asterias Biotherapeutics late last year, the company that had been conducting the studies. BioTime is now planning to meet with the Food and Drug Administration (FDA) later this year to discuss next steps for the therapy.

You can read more about this study HERE.